召集会议
发表于 2025-3-21 16:41:39
书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0622557<br><br> <br><br>书目名称Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0622557<br><br> <br><br>
草本植物
发表于 2025-3-21 23:35:04
http://reply.papertrans.cn/63/6226/622557/622557_2.png
NEX
发表于 2025-3-22 03:30:47
Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroend dual-targeting chimeric molecules. Conjugation of SST analogs with radionuclides has also been used for peptide-receptor-targeted radiotherapy (PRRT) in advanced NETs, with promising results. This chapter summarizes key preclinical and clinical data on the antisecretory and antitumor effects of S
ALE
发表于 2025-3-22 05:54:29
Streptozocin-Based Chemotherapy: Still a Standard of Care for Neuroendocrine Tumours?, therapies and this may be important in those who are symptomatic from tumour burden and those with locally advanced disease who may be down-staged for resection. The role of Ki67 and other predictive markers requires further assessment in prospective studies as does the relative efficacy of alterna
试验
发表于 2025-3-22 12:23:19
http://reply.papertrans.cn/63/6226/622557/622557_5.png
GUISE
发表于 2025-3-22 13:46:57
Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors, trial. In this later study, sunitinib demonstrated significant benefits in terms of progression-free survival and response rate in patients with advanced well-differentiated pancreatic neuroendocrine tumors. The safety profile in this patient population was consistent with previously reported data
auxiliary
发表于 2025-3-22 19:49:37
Clinical Management of Targeted Therapies in Neuroendocrine Tumours,ons, and providing strategies to overcome them is a further important component of patient care. At the core of clinical management is effective communication between patients and physicians, which ensures patients are fully involved in decisions concerning their care, and will allow advances in the
拥护者
发表于 2025-3-22 22:38:38
Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies,ving targeted agents. In this chapter, we aimed to review the various imaging techniques used to characterize neuroendocrine tumors in routine clinic and clinical trials. We also challenge the potential advantages of those imaging techniques for the evaluation of response in patients with neuroendoc
中世纪
发表于 2025-3-23 02:01:14
Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumorsesponse) resistance to antiangiogenic agents and mTOR inhibitors, using data available from preclinical and clinical studies in various malignancies. Herein, we also describe how these general mechanisms of resistance may emerge in patients with PNET treated with sunitinib and everolimus. Overcoming
ECG769
发表于 2025-3-23 08:01:59
http://reply.papertrans.cn/63/6226/622557/622557_10.png